Agendia Hires David Macdonald as Chief Operating Officer, Mark Willig as Executive VP of North American Sales, and Doug Bradley as Vice President of Global Marketing

Irvine, California and Amsterdam (ots/PRNewswire) -
Agendia, a world leader in molecular cancer diagnostics, today
announced the hiring of David Macdonald as the company's Chief
Operating Officer, Mark Willig as Executive Vice President of North
American Sales, and Doug Bradley as Vice President of Global
Marketing. Macdonald has been with Agendia for the past eight months
in a consulting role and will continue to be responsible for
laboratory operations, research and development, product support,
information technology and U.S. human resources. Willig brings with
him a rich background of executive leadership experience in a variety
of commercial roles and will oversee all sales activity in North
America. Bradley will manage all strategic and tactical marketing
activities.

"As Agendia grows it is vital that we continually seek out the
brightest and most innovative minds in the industry to add to our
already stellar team," said Dr. Bernhard Sixt, CEO and co-founder of
Agendia. "We have done just that with the hiring of David, Mark and
Doug, who will help us make more people aware of Agendia's truly
revolutionary technology worldwide."

Macdonald has 25 years of experience commercializing clinical
diagnostic systems and laboratory services for companies such as Nova
Biomedical, Behring Diagnostics, Nichols Institute, Quest
Diagnostics, Nanogen, Nanomix and AltheaDx. He has held CEO and COO
positions for the past 18 years, and holds a Bachelor of Science
degree from Northeastern University in management and finance as well
as an MBA from Babson College in marketing and entrepreneurship.

Willig has held a number of senior leadership positions within
the healthcare industry, including General Manager and Chief
Commercial Officer at Exiqon, VP of Global Sales for Thermo Fisher's
$300 million anatomic pathology business unit, Executive Vice
President of Sales and Marketing at Specialty Labs, Vice President of
Sales at Myriad Genetics, as well as 12 years in commercial roles of
increasing responsibility at Abbott Diagnostics. He holds a Bachelor
of Science degree from the University of Missouri.

Bradley brings a wealth of leadership experience in medical and
pharmaceutical product marketing at companies including Coherent
Medical, Allergan and SenoRx. Most recently, he served as Vice
President of Marketing at Vertos Medical. In his eight years at
Irvine-based SenoRx, Bradley led the company's marketing activities
from its infancy. In this role, Bradley became intimately familiar
with medical devices for the diagnosis and treatment of breast
cancer. During Bradley's time at SenoRx, they received the
"Technology Fast 50" award from Deloitte & Touch in 2006, 2007 and
2008. He holds a Bachelor of Science degree in Microbiology from the
University of Oklahoma and an MBA from Pepperdine University.

About Agendia

Agendia (http://www.Agendia.com) is at the forefront of the
personalized medicine revolution, striving to bring more effective,
individualized treatments within reach of patients. Building on a
cutting-edge genomics platform for tumor gene expression profiling,
the company's tests help physicians more accurately tailor cancer
treatments. Agendia markets four products, with several new genomic
tests under development. In addition, Agendia collaborates with
pharmaceutical companies to develop highly effective personalized
drugs in the area of oncology. Agendia is based in Irvine,
California, and in Amsterdam, the Netherlands.

ots Originaltext: Agendia B.V.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
MEDIA Valerie Carter, Ricochet Public Relations,+1-202-316-0143
Mobile, vcarter@ricochetpr.com